Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Genelux Corp.
Headquarters: San Diego, CA, United States of America
Website: http://www.genelux.com
Year Founded: 2001
Status: Public
Industry Sector: HealthTechnology
CEO: Thomas D. Zindrick
Number Of Employees: 23
Enterprise Value: $321,582,185
PE Ratio: -3.57
Exchange/Ticker 1: NASDAQ:GNLX
Exchange/Ticker 2: N/A
Latest Market Cap: $117,429,904
BioCentury | Aug 28, 2023
Management Tracks
Kurt Graves takes top spot at i2o
Plus: Lourie Zak becomes CFO at Genelux, and updates from Delve Bio, Leo, and Synthetica
BioCentury | Jul 21, 2023
Management Tracks
Janssen vet Vratsanos joins Jnana as CMO
Plus: CureVac’s Splawski lands at Yarrow and updates from Genelux, Cour and more
BioCentury | Nov 16, 2021
Data Byte
The oncolytic virus pipeline
At least 49 oncolytic virus therapies now in development behind the sole FDA-approved product
BioCentury | Feb 29, 2016
Product Development
Infectious enthusiasm
How oncolytic viruses are coming of age in cancer immunotherapy combinations
Items per page:
1 - 10 of 21